Denise M. Wolf, PhD, discusses the methods used to conduct the I-SPY2 study and the implications that immune biomarkers could have on selecting treatment for patients with hormone receptor–positive, HER2-negative breast cancer in the future.

Related Keywords

San Francisco , California , United States , Denisem Wolf , Michaelj Campbell , , Department Of Laboratory Medicine , University Of California , Laboratory Medicine , Cancer Cell , Investigational Device Exemption , Phd , Ispy2 , Breast Cancer , Asco Annual Meeting ,